Century Therapeutics, Inc. Financials
Century Therapeutics, Inc. (IPSC) reported $109.2M in revenue for fiscal year 2025, up 1556.8% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Top-line expansion improved reported losses, while cash consumption and balance-sheet reshaping remain the dominant operating mechanics.
FY2025 revenue reached$109M , yet operating cash flow remained-$104M . The contrast with the much smaller$17M operating loss means reported commercial activity and near-break-even accounting performance did not translate into cash; the earnings improvement is therefore not yet a cash-conversion story.
The cost base still reflects a development-heavy model: R&D was
The funding structure also changed materially. Total liabilities fell to
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Century Therapeutics, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Century Therapeutics, Inc. scores -0.44, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($403.8M) relative to total liabilities ($64.8M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Century Therapeutics, Inc. passes 3 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, both operating efficiency signals pass.
Century Therapeutics, Inc. reported a net loss of $9.6M while operations used $103.9M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Century Therapeutics, Inc. generated $109.2M in revenue in fiscal year 2025. This represents an increase of 1556.8% from the prior year.
Century Therapeutics, Inc.'s EBITDA was -$4.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 96.7% from the prior year.
Century Therapeutics, Inc. reported -$9.6M in net income in fiscal year 2025. This represents an increase of 92.4% from the prior year.
Century Therapeutics, Inc. earned -$0.14 per diluted share (EPS) in fiscal year 2025. This represents an increase of 91.3% from the prior year.
Cash & Balance Sheet
Century Therapeutics, Inc. recorded an outflow of $104.7M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents an increase of 5.0% from the prior year.
Century Therapeutics, Inc. held $61.9M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
Century Therapeutics, Inc.'s operating margin was -15.8% in fiscal year 2025, reflecting core business profitability. No change is given against fiscal year 2024: its reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Century Therapeutics, Inc.'s net profit margin was -8.8% in fiscal year 2025, showing the share of revenue converted to profit. No change is given against fiscal year 2024: its reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Century Therapeutics, Inc.'s ROE was -6.0% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 72.4 percentage points from the prior year.
Not reported for fiscal year 2025.
Capital Allocation
Century Therapeutics, Inc. invested $95.7M in research and development in fiscal year 2025. This represents a decrease of 10.8% from the prior year.
Century Therapeutics, Inc. invested $848K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 450.6% from the prior year.
Not reported for fiscal year 2025.
IPSC Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | $109.2M+2516.6% | $4.2M+427.4% | $791K |
| R&D Expenses | $19.6M+14.6% | $17.1M | N/A | $12K-100.0% | $26.9M+1.0% | $26.6M-9.5% | $29.4M+7.9% | $27.2M |
| SG&A Expenses | $5.8M-12.0% | $6.6M | N/A | $6.8M-12.4% | $7.8M-7.2% | $8.4M+8.4% | $7.8M-7.2% | $8.4M |
| Operating Income | -$36.5M-54.2% | -$23.7M | N/A | -$36.1M-4.2% | -$34.7M-146.7% | $74.2M+298.9% | -$37.3M-7.2% | -$34.8M |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | $1.8M+22287.5% | -$8K |
| Net Income | -$34.5M-59.6% | -$21.6M | N/A | -$34.4M-5.8% | -$32.5M-142.5% | $76.6M+312.2% | -$36.1M-15.5% | -$31.2M |
| EPS (Diluted) | -$0.17-54.5% | -$0.11+56.0% | -$0.25 | -$0.40-5.3% | -$0.38-142.7% | $0.89+307.0% | -$0.43-16.2% | -$0.37 |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Interest Expense.
IPSC Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $287.0M-12.1% | $326.6M+46.0% | $223.7M-8.6% | $244.7M-14.0% | $284.7M-9.8% | $315.6M-10.6% | $353.2M-9.1% | $388.6M |
| Current Assets | $124.8M-10.3% | $139.0M+15.1% | $120.8M-12.3% | $137.7M-14.0% | $160.2M-5.6% | $169.6M-12.6% | $194.1M-5.8% | $206.0M |
| Cash & Equivalents | $49.6M-2.8% | $51.0M-17.5% | $61.9M+11.4% | $55.5M-2.4% | $56.9M+9.7% | $51.9M-11.3% | $58.4M+11.1% | $52.6M |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $4.7M |
| Total Liabilities | $54.7M-11.6% | $61.8M-4.6% | $64.8M-5.3% | $68.4M-8.6% | $74.8M-0.5% | $75.2M-60.8% | $191.9M-0.6% | $192.9M |
| Current Liabilities | $15.1M+11.1% | $13.6M-32.9% | $20.2M-8.2% | $22.0M+47.4% | $14.9M+3.1% | $14.5M-88.8% | $129.8M+554.8% | $19.8M |
| Total Equity | $232.3M-12.2% | $264.7M+66.6% | $158.9M-9.9% | $176.3M-16.0% | $209.9M-12.7% | $240.4M+49.0% | $161.4M-17.5% | $195.7M |
| Retained Earnings | -$848.1M-4.2% | -$813.6M-2.7% | -$791.9M-2.5% | -$772.7M-4.7% | -$738.3M-4.6% | -$705.8M+9.8% | -$782.3M-4.8% | -$746.3M |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Long-Term Debt.
IPSC Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$19.8M+21.5% | -$25.3M-57.1% | -$16.1M+37.2% | -$25.6M+7.3% | -$27.6M+20.3% | -$34.6M-42.9% | -$24.2M+14.5% | -$28.3M |
| Capital Expenditures | $694K+18.8% | $584K+320.1% | -$139K-28.7% | $195K-38.5% | $317K-33.3% | $475K | N/A | N/A |
| Free Cash Flow | -$20.5M+20.6% | -$25.8M-59.4% | -$16.2M+37.1% | -$25.8M+7.6% | -$27.9M+20.5% | -$35.1M | N/A | N/A |
| Investing Cash Flow | $17.8M+115.8% | -$112.6M-603.6% | $22.4M-9.4% | $24.7M-24.2% | $32.5M+16.5% | $27.9M-8.7% | $30.6M-21.9% | $39.2M |
| Financing Cash Flow | $311K-99.8% | $126.6M+238811.3% | $53K | $0 | $0-100.0% | $120K+119.9% | -$602K-320.5% | $273K |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
IPSC Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | N/A | N/A | N/A | N/A | N/A | 68.0% | -893.7% | -4398.1% |
| Net Margin | N/A | N/A | N/A | N/A | N/A | 70.1% | -864.6% | -3947.7% |
| Return on Equity | -14.9%-6.7pp | -8.2% | N/A | -19.5%-4.0pp | -15.5%-47.3pp | 31.8%+54.2pp | -22.4%-6.4pp | -16.0% |
| Return on Assets | -12.0%-5.4pp | -6.6% | N/A | -14.1%-2.6pp | -11.4%-35.7pp | 24.3%+34.5pp | -10.2%-2.2pp | -8.0% |
| Current Ratio | 8.28-2.0x | 10.25+4.3x | 5.97-0.3x | 6.25-4.5x | 10.72-1.0x | 11.70+10.2x | 1.50-8.9x | 10.39 |
| Debt-to-Equity | 0.240.0x | 0.23-0.2x | 0.410.0x | 0.390.0x | 0.360.0x | 0.31-0.9x | 1.19+0.2x | 0.99 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | -32.1% | N/A | N/A |
Not reported in any period shown, so not listed: Gross Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.
Similar Companies
Where Century Therapeutics, Inc. Ranks
Frequently Asked Questions
What is Century Therapeutics, Inc.'s annual revenue?
Century Therapeutics, Inc. (IPSC) reported $109.2M in total revenue for fiscal year 2025. This represents a 1556.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Century Therapeutics, Inc.'s revenue growing?
Century Therapeutics, Inc. (IPSC) revenue grew by 1556.8% year-over-year, from $6.6M to $109.2M in fiscal year 2025.
Is Century Therapeutics, Inc. profitable?
No, Century Therapeutics, Inc. (IPSC) reported a net income of -$9.6M in fiscal year 2025, with a net profit margin of -8.8%.
What is Century Therapeutics, Inc.'s EBITDA?
Century Therapeutics, Inc. (IPSC) had EBITDA of -$4.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Century Therapeutics, Inc.'s operating margin?
Century Therapeutics, Inc. (IPSC) had an operating margin of -15.8% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Century Therapeutics, Inc.'s net profit margin?
Century Therapeutics, Inc. (IPSC) had a net profit margin of -8.8% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Century Therapeutics, Inc.'s return on equity (ROE)?
Century Therapeutics, Inc. (IPSC) has a return on equity of -6.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Century Therapeutics, Inc.'s free cash flow?
Century Therapeutics, Inc. (IPSC) recorded an outflow of $104.7M in free cash flow during fiscal year 2025. This represents a 5.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Century Therapeutics, Inc.'s operating cash flow?
Century Therapeutics, Inc. (IPSC) recorded an outflow of $103.9M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Century Therapeutics, Inc.'s total assets?
Century Therapeutics, Inc. (IPSC) had $223.7M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Century Therapeutics, Inc.'s capital expenditures?
Century Therapeutics, Inc. (IPSC) invested $848K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Century Therapeutics, Inc. spend on research and development?
Century Therapeutics, Inc. (IPSC) invested $95.7M in research and development during fiscal year 2025.
What is Century Therapeutics, Inc.'s current ratio?
Century Therapeutics, Inc. (IPSC) had a current ratio of 5.97 as of fiscal year 2025, which is generally considered healthy.
What is Century Therapeutics, Inc.'s debt-to-equity ratio?
Century Therapeutics, Inc. (IPSC) had a debt-to-equity ratio of 0.41 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Century Therapeutics, Inc.'s return on assets (ROA)?
Century Therapeutics, Inc. (IPSC) had a return on assets of -4.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
How does Century Therapeutics, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Century Therapeutics, Inc. (IPSC) held $117.1M in cash, cash equivalents and investments, and reported an operating cash outflow of $103.9M over that year. Dividing the one by the other, the reported balance equals about 14 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Century Therapeutics, Inc.'s Altman Z-Score?
Century Therapeutics, Inc. (IPSC) has an Altman Z-Score of -0.44, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Century Therapeutics, Inc.'s Piotroski F-Score?
Century Therapeutics, Inc. (IPSC) has a Piotroski F-Score of 3 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Century Therapeutics, Inc.'s earnings high quality?
Century Therapeutics, Inc. (IPSC) reported a net loss of $9.6M while operations used $103.9M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Century Therapeutics, Inc.?
Century Therapeutics, Inc. (IPSC) scores 58 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.